SINTX Completes First Human Surgery with FDA-Cleared Foot & Ankle Implant — SINTX Technologies, Inc.

Event summary

SINTX completed its first human surgery using the FDA-cleared SINAPTIC® Foot & Ankle Osteotomy Wedge System on March 13, 2026.
The procedure was performed by Dr. Scott Carrington at Emplify Health in La Crosse, Wisconsin.
SINTX's silicon nitride technology is designed to support bone integration and reduce bacterial adhesion.
The SINAPTIC system received FDA 510(k) clearance in October 2025.

The big picture

SINTX's entry into the foot and ankle reconstruction market marks a strategic pivot from its core spine applications. The global orthopedic implant market is valued in the billions, with foot and ankle procedures representing a significant and growing segment. SINTX aims to position silicon nitride as a differentiated biomaterial platform capable of driving future revenue growth and broader surgeon adoption.

What we're watching

Market Expansion: How SINTX will scale its silicon nitride platform beyond spine applications into the foot and ankle reconstruction market.
Surgeon Adoption: The pace at which orthopedic surgeons adopt silicon nitride implants over traditional metal and plastic alternatives.
Commercialization Strategy: Whether SINTX can successfully commercialize the SINAPTIC system to drive long-term revenue growth.